The selection and combination of these functional groups can be customized according to payload characteristics, tumor microenvironment features, and therapeutic strategy, enabling highly selective and efficient drug release
Wegovy (semaglutide 2.4 mg) is a prescription medicine licensed in the UK for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or obstructive sleep apnoea
Molecular mechanisms of N-acetylcysteine actions
As of June 2025, retatrutide has not received marketing authorisation from the MHRA or EMA and cannot be legally prescribed or dispensed in the UK outside of an authorised clinical trial
Yet in an interim analysis of the phase 3 trial, ocedurenone failed to meet its primary end point of a reduction in systolic blood pressure from baseline to week 12
doi:10.1016/j.jacc.2025.11.016 McGuire DK, Marx N, Mulvagh SL, et al
